Filgotinib Maleate

CHICAGO — From a 22nd-floor office overlooking the Chicago Riverwalk, in the heart of the Midwest hub’s white-collar downtown district, Lakefront Biotherapeutics’ executives hope to stage the company’s turnaround. It’s here where the work-in-progress rebranding — and remaking — of the 27-year-old drug developer Galapagos is taking shape. The company officially changed its name to Lakefront last week. The new name is partly a reflection of the Chicago lakefront, where CEO Henry Gosebruch likes to run in the mornings to “get ready for the day” and “reflect on things,” as well as the lakes in the area surrounding the company’s corporate base in Mechelen, Belgium. “We had all this capital but no real significant pipeline — just one single asset remaining from the past, TYK2 — so we thought it would make sense to some degree, honor the legacy, but really move forward with a new name and get people excited about what we’re here to build,” Gosebruch said Monday in an in-person interview from his corner office. Click on the image to see the full-sized version A year ago today, the company announced that Gosebruch would immediately step into the CEO post , taking over from Paul Stoffels in a move that diverted from plans announced just weeks earlier. Gosebruch was brought on board to rescue what was once one of Europe’s most valuable biotech companies and create a blueprint for the long term. Gosebruch and his new executive team, including former Horizon Therapeutics CFO Aaron Cox, inherited a massive stockpile of money to reshape Lakefront’s identity. “It’s rare to have 3 billion-plus euros and have the ability to go into any area that’s really exciting,” the CEO said. Gosebruch, Cox and other Lakefront executives have been based in Chicago for years, hence the company’s move to set up a central office there. A year into his tenure, Lakefront is facing another pivotal moment that will determine whether it’s made the right decision. The biotech is about to digest four investigational medicines and the scientists of a San Francisco T cell engager company called Ouro Medicines. It’s doing the billion-dollar deal with the help of partner Gilead Sciences as they attempt to prove the emerging modality in rare autoimmune diseases. Ouro became the top choice after Lakefront narrowed its deal hunt to the BCMAxCD3 space last fall. The other main contender was Candid Therapeutics. But Ouro’s clinical data, rare patient populations and Lakefront’s familiarity with some of the executive team helped seal the deal. The restructured Lakefront is attempting to do what it couldn’t achieve with its last rehashing in 2022. Stoffels, the former Johnson & Johnson R&D captain, took over Galapagos in 2022 after the company floundered. It had lined up an eye-popping $5 billion alliance with Gilead in 2019 and got a JAK inhibitor drug approved in Europe. But the company faced hurdles getting that asset, named filgotinib, to market in the US . So Stoffels and his new team tried to champion the promise of cell therapies instead. Galapagos signed multiple deals in the space, including manufacturing agreements , a community blood center partnership , and an expansion into China . These efforts didn’t pan out. Stoffels and his team exited last year. The cell therapy ambitions were officially put to bed after an attempt to divest the business was unsuccessful. “It was just not commercially viable. The data was interesting, but it was just too late in the ex vivo CAR-T [landscape],” Gosebruch said Monday. “There’s been lots of moves into in vivo and many others have now either shut down their franchises or sold.” Lakefront is staking its future on T cell engagers, which have intrigued many other drugmakers, spurring multiple deals across both cancer and autoimmune diseases in recent quarters. The modality could potentially be more easily made and delivered than cell therapies, among other advantages. Earlier this spring, Lakefront and Gilead teamed up on a deal to buy Ouro for $1.68 billion upfront, split evenly between the partners. The multipronged deal is slated to close this quarter. The acquisition gives Lakefront and Gilead access to a BCMAxCD3 T cell engager known as gamgertamig. It derives from China-based Keymed Biosciences. They also get three preclinical assets developed in-house at Ouro. Few details of the journey to the Ouro-Gilead-Lakefront alliance have been disclosed to date. As a private company, Ouro isn’t required to publicly lay out the moves that led to the acquisition. Lakefront began surveying the landscape of TCEs in earnest in the fall of 2025, Gosebruch said, around the time the company decided to ice its cell therapy plans. Instead of focusing on CD19xCD3 TCEs like other companies , Lakefront decided to hone in on BCMAxCD3 opportunities. “As more and more data emerged, our team was more convinced — and this is similar to Candid — that BCMA would ultimately be the better horse to ride on,” Gosebruch said. Gosebruch said Lakefront “did a lot of work” looking at both Ouro and Candid Therapeutics, but “ultimately decided Ouro is the one to really get aggressive on.” “We’re very familiar with Candid, and we think it’s a good team, good asset. When we had a choice, we and Gilead chose Ouro, and that was based on some good insights on what they’re doing,” Gosebruch said. Candid wound up finding a new home, too. Belgian drugmaker UCB said earlier this month it’s buying the company for $2 billion upfront with the potential for up to $200 million more in milestones. “I don’t think it’s a Coke [versus] Pepsi type of setup,” Gosebruch said. “There’s a lot of room to do a lot of good in a lot of diseases, and there’ll be a place for both of these molecules.” Lakefront looked at Ouro’s efficacy data in more than 60 global patients, went to China to verify some of that data, and “got very comfortable” with the side effect profile of gamgertamig, Gosebruch said. He noted Ouro had already identified a subcutaneous dosing regimen that minimized risk for cytokine release syndrome. The team at Lakefront liked that Ouro was “very smartly using this technology to go after more orphan or niche-ier immunology diseases where there’s almost no existing treatments,” Gosebruch said. That includes indications such as autoimmune hemolytic anemia and immune thrombocytopenia. Steroids are essentially the only medicines in those patient populations, he said. “You can get very rapid proof-of-concept, which then means in financial terms, you don’t really need a lot of investment to get that proof-of-concept,” Gosebruch said. The pivotal studies will be in the “zip code” of 100 patients, he said. Once Lakefront launches into those smaller markets, they could explore larger indications like myasthenia gravis and rheumatoid arthritis, Gosebruch said. It’s in the smaller biotech market of Chicago where Gosebruch and his executive partners hope to chart a turnaround. They’ll look to stand out, as Galapagos did in Belgium, for many years to come.

Galapagos’ name change to Lakefront Biotherapeutics approved at the Company’s EGM (Euronext & NASDAQ: LKFT) Collaboration Agreement with Gilead to advance potential First and Best-in-Class T Cell Engager expected to close in the Second Quarter of 2026 Following this transaction, including estimated associated R&D spend until first approval, the Company will continue to have a majority of its current cash remaining for additional strategic transactions and other capital allocation priorities Year-end 2026 cash and financial investments balance expected to be approximately €2B Management to host conference call on May 7, 2026, at 14:00 CET / 8:00 am ET Mechelen, Belgium ; May 6, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today reported its financial results for the first quarter of 2026 and provided a business update. “Having joined the company just one year ago, I’m thrilled with our progress. I am looking forward to consummating our partnership with Gilead and adding Ouro Medicines’ talented team and its portfolio of programs to our Company, including the potential first and best in class T cell engager in autoimmune diseases, gamgertamig (OM336). We are excited that our Company is rebranding as Lakefront Biotherapeutics as this name reflects our Company’s strategic evolution,” said Henry Gosebruch, Chief Executive Officer of Galapagos. Aaron Cox, Chief Financial Officer of Galapagos, added, “Following the anticipated use of cash to fund our collaboration with Gilead concerning its acquisition of Ouro Medicines, the Company will remain robustly capitalized and will have increased flexibility, including the ability to spend up to $500 million for business development independent of Gilead and not subject to our 2019 Option, License, and Collaboration Agreement with Gilead. This would also include the potential to use up to $150 million of that $500 million for share repurchases to the extent that we have available distributable reserves. In addition to the upfront consideration of $837.5 million, we anticipate additional 2026 Ouro-related cash expenditures to be in the range of €60-75 million, inclusive of R&D costs, one-time transaction costs and assuming a mid-year closing of the transaction.” First Quarter 2026 Business Update On March 31, 2026, the Company announced that it has entered into a binding agreement (the “Framework Agreement”) with Gilead Sciences, Inc. (“Gilead”) (the “Transaction”) in connection with Gilead’s definitive agreement to acquire all of the outstanding equity interests of US-based Ouro Medicines, LLC (“Ouro”), a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases. Gamgertamig (OM336) is a clinical stage BCMAxCD3 T cell engager designed to enable rapid and deep plasma and B cell depletion following a short duration, subcutaneously administered treatment course. In ongoing Phase 1/2 clinical studies, gamgertamig has demonstrated transformative efficacy and a differentiated safety pro a single treatment cycle in severe antibody-mediated orphan diseases, including autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). Gamgertamig has been granted both Fast Track and Orphan Drug Designation by the U.S. FDA for the treatment of AIHA and ITP and is expected to enter registrational studies as early as 2027. BCMA-targeted T cell engagers are being investigated as a precision approach for severe inflammatory and autoimmune diseases by eliminating pathogenic B cells and plasma cells. By redirecting a patient’s own T cells toward BCMA-expressing plasma cells, clinical data suggest these agents can reduce inflammation, improve organ-level disease, and in some cases enable durable, drug-free remission without ongoing immunosuppression. Update on Binding Agreement with Gilead The Company expects the Transaction to close in the second quarter of 2026, subject to the fulfillment of the closing conditions. Galapagos expects to assume substantially all of Ouro’s operating assets and personnel (approximately 20 employees), such that the Company would obtain an operating business. Galapagos and Gilead will equally split the upfront payment of $1.675 billion (~€1.425 billion 1 ), subject to customary adjustments, and contingent milestone payments of up to $500 million (~€425 million 1 ). Galapagos and Gilead will collaborate on the development of gamgertamig, with Galapagos responsible for the development costs through initiation of registrational studies, after which the development costs will be shared equally. Galapagos is eligible for up to $100 million in development milestones payments for gamgertamig in certain other indications. Galapagos will fund its share of payments owed to KeyMed Biosciences Chengdu Co., Ltd. (“KeyMed”), comprising 25% of the milestone payments and 50% of the royalty payments that become due to KeyMed with respect to gamgertamig products. Based on Ouro’s original transaction with Keymed, Keymed is entitled to total development and commercial milestones of up to $610 million and tiered royalties of 7%-14% of net sales for gamgertamig. Gilead will retain sole worldwide commercialization rights, including all related costs, globally outside of Keymed’s territories, and Galapagos will receive tiered royalties of 20%–23% on net sales of gamgertamig from Gilead. Galapagos will gain a preclinical portfolio of three additional autoimmune focused programs originally from Ouro, with an opt-in for Gilead for a 50/50 profit split post clinical proof-of-concept for $75 million (~€64 million 1 ) per program. The proposed arrangements will amend the existing collaboration terms with Gilead to designate $500 million (~€425 million 1 ) of Galapagos’ cash available for R&D or strategic transactions outside of Gilead partnerships, including up to $150 million (~€128 million 1 ) of this $500 million (~€425 million 1 ) for potential return of capital, subject to certain limitations. In addition to the upfront payment of $837.5 million (~€713 million 1 ), the range of spending expected (including transaction expenses, operating expenses, milestones, and royalties) in 2026 is €60-€75 million. Following this transaction, including estimated associated R&D spend until first approval, the Company will continue to have a majority of its current cash of approximately €3B remaining for additional strategic transactions and other capital allocation priorities. 1 Converted at a rate €/$ 1.175, consistent with year-end 2025 CORPORATE At the Company’s Annual and Extraordinary Shareholders’ Meeting held on April 28, 2026 (the “AGM” and “EGM”) all proposed resolutions were approved (see: press release of April 28, 2026 ), among other items: the name change to Lakefront Biotherapeutics, with effect as of May 8, 2026. Our ticker on Euronext and NASDAQ (ADRs) will change to LKFT; Gino Santini’s appointment as a member of our Board of Directors, and pursuant to a vote of our Board of Directors, Gino became the new Chair of our Board of Directors. Gino replaces Jérôme Contamine, whose four-year mandate as a member of the Board of Directors ended upon the conclusions of the AGM; the authorization to acquire the Company’s own shares. In April 2026, Coultreon Biopharma BV (“Coultreon”), previously named Onco3R Therapeutics BV, announced the closing of an oversubscribed $125 million Series A financing round. The financing will support the clinical development of Coultreon’s lead immunology program, COL-5671 (formerly O3R-5671), a highly selective SIK3 inhibitor in Phase 1, with potential to demonstrate clinical proof-of-concept in 2027. COL-5671 was initially developed by Galapagos and ownership was fully transferred to Coultreon in April 2025, when Galapagos provided seed financing to the company with a convertible note investment that converted into equity ownership in Coultreon in connection with Series A financing. IMMUNOLOGY SMALL MOLECULE PIPELINE As part of our ongoing efforts to maximize the value of the GLPG3667 program for both patients and Galapagos, we are evaluating all strategic options. The GALACELA SLE study with GLPG3667 is currently ongoing, and the final Week 48 data are expected in the second quarter of 2026. ONCOLOGY CAR-T CELL THERAPY UPDATE The Company announced in January 2026 the start of the wind-down of its cell therapy activities. The wind-down remains on schedule and is expected to be substantially completed by the end of the third quarter of 2026. The Company continues to expect 2026 one-time cash costs related to the wind-down to be in the range of €125 million to €175 million. Financial Guidance Galapagos currently estimates 2026 cash spend related to Ouro of approximately €775 million to €790 million, inclusive of the upfront payment, transaction costs, and operating costs assuming a mid-year transaction closing. The Company expects its year end 2026 cash and financial investments balance to be in the range of €1.975 billion to €2.050 billion, which reflects a reduction in prior guidance due to expected cash usage related to the Ouro investment and a corresponding reduction in interest income. Galapagos continues to expect one-time cash restructuring costs of €125 million to €175 million related to the ongoing wind-down of the cell therapy activities. All figures assume a EUR/USD exchange rate of 1.175, consistent with year-end 2025. These estimates are subject to change and depend on the timing of closing, final transaction scope, integration activities, exchange rate fluctuations, and remaining cell therapy wind-down costs. Financial Performance Key figures for the first quarter of 2026 (consolidated) (€ millions, except basic & diluted earnings/loss (-) per share) March 31, 2026 March 31, 2025 % Change Supply revenues 4.9 13.8 -64% Collaboration revenues 1.6 61.2 -97% Total net revenues 6.5 75.0 -91% Cost of sales (4.8) (13.8) -65% R&D expenses (31.0) (182.7) -83% G&A 1 and S&M 2 expenses (35.5) (43.8) -19% Other operating income 1.1 6.6 -83% Operating loss (63.7) (158.7) Fair value adjustments and net exch­ange differences 64.3 (9.4) Net other financial result 13.4 11.8 Income taxes (0.1) 1.8 Net profit/loss (-) from continuing operations 13.9 (154.5) Net profit from discontinued operations, net of tax 0.6 1.1 Net profit/loss (-) of the period 14.5 (153.4) Basic and diluted earnings/loss (-) per share (€) 0.2 (2.3) Financial investments, cash & cash equivalents 2,982.2 3,297.3 Details of the financial results for the first quarter of 2026 Total operating loss from continuing operations for the first three months of 2026 amounted to €63.7 million, compared to an operating loss of €158.7 million for the first three months of 2025. The operating loss in 2025 was negatively impacted by the executed strategic reorganization announced in January 2025, for €111.0 million. This was mainly reflected in severance costs of €47.5 million, costs for early termination of collaborations of €42.1 million and impairment on fixed assets related to small molecules activities of €10.2 million, professional services costs of €6.6 million and €4.2 million accelerated non-cash cost recognition for subscription right plans. Total net revenues amounted to €6.5 million for the first three months of 2026, compared to €75.0 million for the first three months of 2025. The revenue recognition related to the exclusive access rights granted to Gilead for Galapagos’ drug discovery platform amounted to €57.6 million for the first three months of 2025. The deferred income related to the drug discovery platform was fully released in revenue at the end of 2025. Cost of sales amounted to €4.8 million for the first three months of 2026, compared to €13.8 million for the first three months of 2025, and related to the supply of Jyseleca® to Alfasigma under the transition agreement. The related revenues are reported in total net revenues. R&D expenses amounted to €31.0 million for the first three months of 2026, compared to €182.7 million for the first three months of 2025. In the first three months of 2025, the Company recorded increased personnel expenses (mainly related to severance costs), an impairment on fixed assets (related to small molecules programs) and a provision for early termination of collaboration agreements. On top, due to the wind-down of the cell therapy activities the spending in the CAR-T programs decreased in the first three months of 2026 as compared to the first three months of 2025. S&M and G&A expenses amounted to €35.5 million for the first three months of 2026, compared to €43.8 million for the first three months of 2025. This decrease was mainly due to lower personnel costs (primarily severance costs). Other operating income amounted to €1.1 million for the first three months of 2026, compared to €6.6 million for the first three months of 2025, mainly driven by lower grant and R&D incentives income. Net financial income amounted to €77.7 million for the first three months of 2026, compared to net financial income of €2.4 million for the first three months of 2025. Fair value adjustments and net currency exchange results amounted to a positive amount of €64.3 million for the first three months of 2026, compared to a negative amount of €9.4 million for the first three months of 2025, and were primarily attributable to €40.0 million of positive changes in fair value of financial investments and €23.8 million of unrealized currency exchange gains on our cash and cash equivalents and financial investments at amortized cost in U.S. dollars. Net other financial income amounted to €13.4 million for the first three months of 2026, compared to net other financial income of €11.8 million for the first three months of 2025. Net interest income amounted to €12.9 million for the first three months of 2026, compared to €12.0 million of net interest income for the first three months of 2025. Fair value gains and interest income derived from cash, cash equivalents and financial investments excluding any currency exchange results amounted to €24.4 million for the first three months of 2026 (compared to €24.9 million for the same period last year). The Company reported a net profit from continuing operations of €13.9 million for the first three months of 2026, compared to a net loss from its continuing operations of €154.5 million for the first three months of 2025. Net profit from discontinued operations related to Jyseleca® amounted to €0.6 million for the first three months of 2026, compared to net profit amounting to €1.1 million for the first three months of 2025. Galapagos reported a net profit of €14.5 million for the first three months of 2026, compared to a net loss of €153.4 million for the first three months of 2025. Cash position Financial investments and cash and cash equivalents totaled €2,982.2 million on March 31, 2026, as compared to €2,998.0 million on December 31, 2025. The cash and cash equivalents and financial investments included $2,546.4 million held in U.S. dollars ($2,159.0 million on December 31, 2025) which could generate foreign exchange gains or losses in the financial results in accordance with the fluctuation of the EUR/U.S. dollar exchange rate as the Company’s functional currency is EUR (translated at a rate of 1.1498 €/$ at March 31, 2026). Total net decrease in cash and cash equivalents and financial investments amounted to €15.8 million during the first three months of 2026, compared to a net decrease of €20.5 million during the first three months of 2025. This net decrease was composed of (i) €77.9 million of operational cash burn 3 , which includes cash in of €16.1 million related to the return on financial investments, (ii) €60.8 million of positive exchange rate differences, positive changes in fair value of current financial investments, variation in accrued interest income, (iii) €1.0 million acquisition of equity investments, and (iv) €2.3 million of net cash in related to the sale of subsidiaries. Conference call and webcast presentation Galapagos will host a conference call on May 7, 2026, at 14:00 CET / 08:00 AM ET. To participate, please register using this link . Dial-in details will be provided upon registration. Participants can join the call 10 minutes before the start time using the access information received by email or via the “call me” feature. The live call and presentation will be available on www. glpg.com or via the following link . A replay and related materials will be available shortly after the call in the investors section of the website. About Galapagos Galapagos (to be renamed Lakefront Biotherapeutics as of May 8, 2026) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Galapagos prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas. For more information, visit or follow us on LinkedIn or X . For further information, contact Galapagos: Investor Relations Sherri Spear +1 412 522 6418 sherri.spear@glpg.com Forward-looking statements This press release contains forward-looking statements, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,’ “explore,” “further” as well as similar expressions. These statements include, but are not limited to, the guidance from management regarding our financial results and statements on cash position (including guidance regarding the expected results and operational use of cash for the fiscal year 2026 and statements regarding foreign exchange gains or losses in accordance with the fluctuations of the EUR/U.S. dollar exchange rate); statements regarding our business development strategy, including statements regarding our name change to Lakefront Biotherapeutics and our potential partnering or acquisition opportunities, including with the collaboration arrangements between us and Gilead, and the final terms and expected benefits of such opportunities and collaboration; statements regarding the proposed acquisition by Gilead of Ouro and our proposed collaboration with Gilead on Ouro’s portfolio; statements relating to the expected benefits and potential of gamgertamig and BCMA targeted T cell engagers; statements regarding the potential attributes and benefits of our product candidates and partnered and licensed programs, statements regarding our investments in other companies, including Coultreon and the clinical development of its product candidate COL-5671, and any of our future product candidates or approved products, if any, including statements regarding the expected timing, design and readouts of our ongoing and planned preclinical studies and clinical trials, including but not limited to GLPG3667 in SLE and DM, including recruitment for trials and interim or topline results for trials and studies in our portfolio, statements regarding the potential attributes and benefits of our product candidates, statements regarding our commercialization efforts for our product candidates and any of our future approved products, if any; statements regarding the wind down of our cell therapy activities, including statements regarding the expected costs and benefits of such wind down, the anticipated reduction in work force and related site closures, and the expected timeline for completing such wind down. Galapagos cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, the risk that our expectations and management’s guidance regarding our 2026 operating expenses, cash position and other financial estimates may be incorrect (including because one or more of its assumptions underlying our revenue or expense expectations may not be realized); the risks associated with the changes to our capital allocation strategies; the risk that the potential acquisition by Gilead of Ouro Medicines is not consummated in the expected timing and terms, or at all; the risk that our collaboration with Gilead is not consummated in the expected timing or at all (including as a result of our related party procedures and our ability to satisfy legal and regulatory requirements), or if consummated, the risk that we are not able to realize the benefits of such collaboration; the risk that final terms of such collaboration materially deviate from those described in this press release; the risk that we will not be able to execute on our currently contemplated business plan or strategy and/or will revise our business plan or strategy; risks related to our ability to successfully identify, pursue and consummate new transformational business development transactions, including our ability to identify product candidates that will have commercial success and/or be profitable; risks related to our ability to satisfy legal and regulatory requirements (including antitrust requirements related to both us and Gilead), amend our existing agreement with Gilead, and address other factors outside our control that may impact our ability to consummate any potential transaction timely or at all, or if consummated, to realize the benefits of such transaction; the risks related to our ability to successfully implement the wind down of our cell therapy activities within the expected timeframe or at all, or if implemented, will achieve its anticipated economic benefits; risks related to negative impacts of the wind down (whether or not completed) on our stock price, employee retention, business relationships and business generally (including risk of litigation); risks associated with Galapagos’ product candidates and partnered and licensed programs; the risk that ongoing and future clinical trials may not be completed in the currently envisaged timelines or at all; the inherent risks and uncertainties associated with competitive developments, clinical trials, recruitment of patients, product development activities and regulatory approval requirements (including the possibility of unfavorable new clinical data and further analyses of existing clinical data, the risks related to clinical failure at any stage of clinical development; uncertainty inherent to patient enrollment and enrollment rate, our ability to use and expand our drug discovery efforts, competition, side effects caused by our product candidates, delays in obtaining regulatory approval of manufacturing processes and facilities or disruptions in manufacturing processes, and the rate and degree of market acceptance of our products, if approved), the possibility of differing perspectives and requirements by local regulatory authorities, and new or changing government regulations; risks related to the commercialization of our products, if approved; risks related to our ability to implement our business model, strategic plans for our business, product candidates and technology; risks related to the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; risks related to our ability to enter into strategic arrangements and strategic collaboration agreements; risks related to our ability to maintain and establish collaborations; risks related to our ability to attract and retain qualified employees and key personnel); risks related to our reliance on collaborations with third parties (including, but not limited to, our collaboration partner Gilead); the risk that our estimates regarding the commercial potential of our product candidates (if approved) or expectations regarding the costs and revenues associated with the commercialization rights may be inaccurate; and risks related to geopolitical conflicts and macro-economic events. A further list and description of these risks, uncertainties and other risks can be found in our filings and reports with the Securities and Exchange Commission (SEC), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the results of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation. i General and administrative ii Sales and marketing iii The operational cash burn (or operational cash flow if this liquidity measure is positive) is equal to the increase or decrease in the cash and cash equivalents (excluding the effect of exchange rate differences on cash and cash equivalents), minus: • the net proceeds, if any, from share capital and share premium increases included in the net cash flows generated from/used in (-) financing activities • the net proceeds or cash used, if any, related to the acquisitions or disposals of businesses; the acquisition of financial assets held at fair value through other comprehensive income; the movement in restricted cash and movement in financial investments, if any, the cash advances and loans given to third parties, if any, included in the net cash flows generated from/used in (-) investing activities • the cash used for other liabilities related to the acquisition or disposal of businesses, if any, included in the net cash flows generated from/used in (-) operating activities. This alternative liquidity measure is in the view of the Company an important metric for a biotech company in the development stage. The operational cash burn for the first three months of 2026, amounted to €77.9 million and can be reconciled to the cash flow statement by considering the decrease in cash and cash equivalents of €21.8 million, adjusted by (i) the net sale of financial investments amounting to €54.8 million, (ii) the cash-in related to the sale of subsidiaries of €2.3 million, and (iii) the acquisition of equity investments of €1.0 million. Addendum Consolidated statements of income and comprehensive income/loss (-) (unaudited) Consolidated income statement Three months ended March 31 (thousands of €, except per share data) 2026 2025 Supply revenues 4,905 13,780 Collaboration revenues 1,576 61,197 Total net revenues 6,481 74,977 Cost of sales (4,799) (13,729) Research and development expenses (30,962) (182,752) Sales and marketing expenses (2,770) (4,174) General and administrative expenses (32,735) (39,623) Other operating income 1,082 6,593 Operating loss (63,703) (158,708) Fair value adjustments and net currency exchange differences 64,241 (9,443) Other financial income 13,555 12,564 Other financial expenses (137) (780) Profit/loss (-) before tax 13,956 (156,367) Income taxes (70) 1,814 Net profit/loss (-) from continuing operations 13,886 (154,553) Net profit from discontinued operations, net of tax 606 1,150 Net profit/loss (-) 14,492 (153,403) Net profit/loss (-) attributable to: Owners of the parent 14,492 (153,403) Basic and diluted earnings/loss (-) per share 0.22 (2.33) Basic and diluted earnings/loss (-) per share from continuing operations 0.21 (2.35) Consolidated statement of comprehensive income/loss (–) Three months ended March 31 (thousands of €) 2026 2025 Net profit/loss (-) 14,492 (153,403) Items that will not be reclassified subsequently to profit or loss: Fair value adjustment financial assets held at fair value through other comprehensive income 9 (2,005) Items that may be reclassified subsequently to profit or loss: Translation differences, arisen from translating foreign activities (262) (533) Other comprehensive loss, net of income tax (253) (2,538) Total comprehensive income/loss (-) attributable to: Owners of the parent 14,239 (155,941) Total comprehensive income/loss (-) attributable to owners of the parent arises from: Continuing operations 13,633 (157,091) Discontinued operations 606 1,150 Total comprehensive income/loss (-), net of income tax 14,239 (155,941) Consolidated statements of financial position (unaudited) (thousands of €) March 31, 2026 December 31, 2025 Assets Intangible assets other than goodwill 746 848 Property, plant and equipment 76,950 80,663 Deferred tax assets 163 195 Non-current R&D incentives receivables 114,575 126,662 Non-current contingent consideration receivable 46,796 47,750 Equity investments 47,933 46,809 Other non-current assets 2,954 2,959 Convertible loan 21,575 21,175 Non-current assets 311,692 327,061 Inventories 17,693 22,493 Trade and other receivables 21,738 20,706 Current R&D incentives receivables 32,296 31,208 Current financial investments 2,915,435 2,910,180 Cash and cash equivalents 66,805 87,868 Other current assets 4,075 7,002 Current assets from continuing operations 3,058,042 3,079,457 Assets in disposal group classified as held for sale 2,695 - Total current assets 3,060,737 3,079,457 Total assets 3,372,429 3,406,518 Equity and liabilities Share capital 293,937 293,937 Share premium account 2,736,994 2,736,994 Other reserves (8,628) (8,637) Translation differences 2,735 2,997 Accumulated result 228,331 210,577 Total equity 3,253,369 3,235,868 Non-current lease liabilities 4,851 5,186 Other non-current liabilities 13,785 12,601 Non-current liabilities 18,636 17,787 Current lease liabilities 1,584 1,729 Trade and other liabilities 95,766 104,647 Provisions 2,130 45,499 Current tax payable 912 956 Current deferred income 32 32 Current liabilities 100,424 152,863 Total liabilities 119,060 170,650 Total equity and liabilities 3,372,429 3,406,518 Consolidated cash flow statements (unaudited) Three months ended March 31 (thousands of €) 2026 2025 Net profit/loss (-) of the period 14,492 (153,403) Decrease in provisions (43,371) - Adjustment for non-cash transactions (57,849) 81,056 Adjustment for items to disclose separately under operating cash flow (12,268) (13,796) Adjustment for items to disclose under investing and financing cash flows (3,546) (9,105) Change in working capital other than deferred income 7,930 111,624 Decrease in deferred income - (59,364) Cash used in operations (94,612) (42,988) Interest paid (64) (208) Interest received 12,012 4,813 Corporate taxes paid (86) (224) Net cash flows used in operating activities (82,750) (38,607) Purchase of property, plant and equipment (123) (5,095) Purchase of intangible fixed assets - (155) Proceeds from disposal of property, plant and equipment 1,317 - Purchase of financial investments (50,145) (340,000) Investment income received related to financial investments 4,136 7,768 Sale of financial investments 105,000 391,802 Convertible loan issued to third party - (1,500) Cash in from the disposal of subsidiaries, net of cash disposed of 2,343 31,925 Acquisition of equity investments held at fair value through other comprehensive income (1,031) - Net cash flows generated from investing activities 61,497 84,745 Payment of lease liabilities (510) (1,011) Net cash flows used in financing activities (510) (1,011) Increase/decrease (-) in cash and cash equivalents (21,763) 45,127 Cash and cash equivalents at beginning of the period 87,868 64,239 Increase/decrease (-) in cash and cash equivalents (21,763) 45,127 Effect of exchange rate differences on cash and cash equivalents 700 (1,299) Cash and cash equivalents at end of the period 66,805 108,067 Consolidated statements of changes in equity (unaudited) (thousands of €) Share capital Share premium account Translation differences Other reserves Accumulated result Total On January 1, 2025 293,937 2,736,994 3,472 (3,158) (134,306) 2,896,939 Net loss (153,403) (153,403) Other comprehensive loss (533) (2,005) (2,538) Total comprehensive loss (533) (2,005) (153,403) (155,941) Share-based compensation 6,896 6,896 On March 31, 2025 293,937 2,736,994 2,939 (5,163) (280,813) 2,747,894 On January 1, 2026 293,937 2,736,994 2,997 (8,637) 210,577 3,235,868 Net profit 14,492 14,492 Other comprehensive income/loss (-) (262) 9 (253) Total comprehensive income/loss (-) (262) 9 14,492 14,239 Share-based compensation 3,262 3,262 On March 31, 2026 293,937 2,736,994 2,735 (8,628) 228,331 3,253,369 Attachment Attachment Galapagos First Quarter Earnings 2026 PR - FINAL CLEAN